在基尔斯鼠肉瘤病毒 (+) 非小细胞肺癌新兴疗法
Anastasia Karachaliou1, Elias Kotteas1, Oraianthi Fiste1
1Oncology Unit, Third Department of Internal Medicine and Laboratory, Medical School, National and Kapodistrian University of Athens, "Sotiria" General Hospital, 11527 Athens, Greece.
针对基斯大鼠肉瘤病毒 (KRAS) 突变,特别是KRAS-G12C,为非小细胞肺癌 (NSCLC) 治疗提供了新的希望. 研究探讨了新的抑制剂和组合策略,以克服耐药性和个性化肺癌治疗.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 基尔斯鼠肉瘤病毒 (KRAS) 是人类癌症中普遍存在的癌基因,特别是非小细胞肺癌 (NSCLC).
- 从历史上看,KRAS突变,特别是KRAS-G12C,在治疗上具有挑战性.
- 在KRAS-G12C中识别开关II区域使得直接抑制剂的开发成为可能.
研究的目的:
- 审查KRAS蛋白的基本生物学和突变特征.
- 总结当前和新兴的治疗策略,治疗KRAS突变肺癌.
- 讨论克服对 KRAS 向疗法的耐药性的方法.
主要方法:
- 关于KRAS生物学,突变亚型和向治疗的文献综述.
- 对FDA批准的KRAS-G12C抑制剂 (索托拉西布,阿达格拉西布) 的分析.
- 检查正在进行的关于组合策略和抵抗机制的研究.
主要成果:
- 像索托拉西布和阿达格拉西布这样的KRAS-G12C抑制剂在预先治疗的NSCLC患者中显示出有效性.
- 耐药性机制限制了当前KRAS抑制剂的长期有效性.
- 结合疗法正在研究,以提高治疗结果.
结论:
- 向KRAS突变,特别是KRAS-G12C,代表了NSCLC治疗的重大进展.
- 克服耐药性对于最大化新型KRAS抑制剂的益处至关重要.
- 个性化治疗策略对于治疗具有KRAS驱动突变的肺癌至关重要.
更多相关视频
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy
